173 related articles for article (PubMed ID: 34052738)
1. Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents.
Fan TY; Yang YX; Zeng QX; Wang XL; Wei W; Guo XX; Zhao LP; Song DQ; Wang YX; Wang L; Hong B
Bioorg Chem; 2021 Aug; 113():104994. PubMed ID: 34052738
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
Dong B; Li H; Singh AB; Cao A; Liu J
J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.
Li H; Dong B; Park SW; Lee HS; Chen W; Liu J
J Biol Chem; 2009 Oct; 284(42):28885-95. PubMed ID: 19687008
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis.
Qiao MQ; Li Y; Yang YX; Pang CX; Liu YT; Bian C; Wang L; Chen XF; Hong B
Eur J Med Chem; 2023 Feb; 247():115047. PubMed ID: 36586297
[TBL] [Abstract][Full Text] [Related]
5. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H
Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167
[TBL] [Abstract][Full Text] [Related]
7. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
[TBL] [Abstract][Full Text] [Related]
8. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE
Ma CY; Shi XY; Wu YR; Zhang Y; Yao YH; Qu HL; Zhang W; Guo YL; Xu RX; Li JJ
Ann Transl Med; 2021 Oct; 9(20):1517. PubMed ID: 34790723
[TBL] [Abstract][Full Text] [Related]
9. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
10. Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells.
Gao WY; Chen PY; Chen SF; Wu MJ; Chang HY; Yen JH
J Agric Food Chem; 2018 Jun; 66(24):6083-6093. PubMed ID: 29862818
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α.
Wang X; Chen X; Zhang X; Su C; Yang M; He W; Du Y; Si S; Wang L; Hong B
EBioMedicine; 2020 Feb; 52():102650. PubMed ID: 32058941
[TBL] [Abstract][Full Text] [Related]
12. Naturally Occurring PCSK9 Inhibitors.
Adorni MP; Zimetti F; Lupo MG; Ruscica M; Ferri N
Nutrients; 2020 May; 12(5):. PubMed ID: 32429343
[TBL] [Abstract][Full Text] [Related]
13. Berberine decreases PCSK9 expression in HepG2 cells.
Cameron J; Ranheim T; Kulseth MA; Leren TP; Berge KE
Atherosclerosis; 2008 Dec; 201(2):266-73. PubMed ID: 18355829
[TBL] [Abstract][Full Text] [Related]
14. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
15. Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Tombling BJ; Lammi C; Bollati C; Anoldi A; Craik DJ; Wang CK
Chembiochem; 2021 Jun; 22(12):2154-2160. PubMed ID: 33755275
[TBL] [Abstract][Full Text] [Related]
16. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
17. Regulation of PCSK9 by nutraceuticals.
Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
[TBL] [Abstract][Full Text] [Related]
18. Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors.
Lammi C; Sgrignani J; Arnoldi A; Lesma G; Spatti C; Silvani A; Grazioso G
J Med Chem; 2019 Jul; 62(13):6163-6174. PubMed ID: 31260298
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
Yang SH; Xu RX; Cui CJ; Wang Y; Du Y; Chen ZG; Yao YH; Ma CY; Zhu CG; Guo YL; Wu NQ; Sun J; Chen BX; Li JJ
Cardiovasc Diabetol; 2018 Apr; 17(1):48. PubMed ID: 29618348
[TBL] [Abstract][Full Text] [Related]
20. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
